L-689502
目录号 : GC32013
L-689502是一个有效的HIV-1蛋白酶(HIV-lprotease)抑制剂，其IC50值为1nM。
Cas No.:138483-63-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
L-689502 is a potent inhibitor of HIV-l protease with an IC50 of 1 nM.
Both L694746 and L-689502 inhibit HIV-l ptotease activity in a concentration-dependent manner. Pepstatin is much less potent than either compound exhibiting an IC50 of 2 μM. L694746 is as potent as L-689502 in inhibiting the HIV-l protease despite being structurally different from L-689502[1].
[1]. Lingham RB, et al. HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1456-61.
Cell experiment: | G689502 (3.3 pmoles in 1 mL of 100% DMSO) is added to cultures that have been growing for 48 hr. The final substrate and DMSO concentrations during the fermentation period are 65 pM and 2%, respectively. The fermentations containing L-689502 are carried out for an additional 72-96 hr prior to be harvested.The whole broth is sequenthdly extracted with methanol (0.5 vol) and acetone (0.5 vol). The supematant containing the derivatives of L-689502 is separated from the mycelia by filtration[1]. |
References: [1]. Lingham RB, et al. HIV-1 protease inhibitory activity of L-694,746, a novel metabolite of L-689,502. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1456-61. | |
| Cas No. | 138483-63-3 | SDF | |
| Canonical SMILES | O=C(OC(C)(C)C)N[C@@H](CC1=CC=CC=C1)[C@@H](O)C[C@@H](CC2=CC=C(OCCN3CCOCC3)C=C2)C(N[C@@H]4[C@H](O)CC5=C4C=CC=C5)=O | ||
| 分子式 | C39H51N3O7 | 分子量 | 673.84 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.484 mL | 7.4202 mL | 14.8403 mL |
| 5 mM | 0.2968 mL | 1.484 mL | 2.9681 mL |
| 10 mM | 0.1484 mL | 0.742 mL | 1.484 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet